Pfizer’s Upjohn Business Sees ‘Expected Drop’ Of 37%

Loss Of Exclusivity For Lyrica Cited As Main Factor

Despite reporting a 37% drop in Upjohn’s first-quarter sales, Pfizer has insisted that the decline was consistent with its expectations for the business. Meanwhile, biosimilars sales have been boosted by US launches as sterile injectables and hospital medicines have seen a lift from COVID-19.

Pink_Arrow
Ahead of its merger with Mylan, sales through Pfizer’s Upjohn unit have declined by almost two fifths • Source: Shutterstock

Pfizer has reported a drop of 37% in revenue from its Upjohn mature brands and off-patent business to $2.022bn in the first quarter of 2020.

Citing loss of exclusivity for Lyrica (pregabalin) – after US generics launched in July 2019 (Also see "Lyrica Rivals...

More from Earnings

More from Business